Figure 2
From: Understanding the mechanisms of aromatase inhibitor resistance
Early changes in microarray expression of oestrogen-regulated genes (KIAA0101, IRS1 (insulin receptor substrate 1), SERPINA3 , TFF1 and TFF3 (trefoil factors 1 and 3) and proliferation markers (CDC2, Cyclin B1, CKS2, thymidylate synthase (TYMS), proliferating cell nuclear antigen (PCNA)) associated with neoadjuvant treatment with letrozole in individual breast cancers clinically resistant to endocrine treatment. Red represents an increase in expression and green a decrease. Brightness of colour indicates degree of change, with the brightest colours representing the greatest change. The left-hand column represents an ER-negative tumour (-ve), the A columns illustrate tumours with a molecular resistant phenotype, the B columns cases exhibiting decreases in expression of oestrogen-regulated genes but not in proliferation-related genes, and the C columns tumours showing molecular sensitivity in both oestrogen-regulated and proliferation-related gene expression.